Introduction {#sec1}
============

Hereditary angioedema (HAE) is a genetic disorder that predisposes an individual to develop vasogenic edema. Prevalence of HAE has been reported to be 1 in 10,000 to 1 in 150,000.[@bib1] The pathogenesis of HAE involves accumulation of extravascular fluid in various tissues via a non-inflammatory and non-allergic mechanism. Clinical manifestations include abrupt onset swelling around eyes, face and extremities; pain abdomen (as a result of bowel edema) and laryngeal edema leading to hoarseness of voice, breathing difficulty and occasionally death.[@bib2], [@bib3] Awareness and recognition of this disease is important as HAE is often misdiagnosed as allergic angioedema or acute abdomen (especially acute appendicitis).[@bib4] This may often lead to inappropriate use of antihistamines, corticosteroids, adrenaline and sometimes even surgical interventions.[@bib4]

Identification of defects in *SERPING1* gene and several other recently identified genes have added significantly to the understanding of pathophysiology of HAE. This disease was initially believed to be a disorder of complement pathway caused by deficiency of C1-inhibitor (C1-INH). However, identification of novel genetic defects (other than *SERPING1* gene) has expanded the spectrum of this disease beyond complement pathway. Genetic defects in some of the intermediate pathway components that may be possible cause HAE are yet to be identified. These advances may bring new therapeutic modalities for the management of HAE. In this review, we aim to update about current understanding in the pathogenesis and recent advances in the genetics of HAE.

Pathophysiology of HAE {#sec2}
======================

Elevated serum levels of bradykinin in the blood are responsible for clinical manifestations seen in patients with HAE. Bradykinin is generated in the body via a complex interaction of various molecules involved in kinin, complement, hemostatic and fibrinolytic pathways ([Fig. 1](#fig1){ref-type="fig"}).[@bib5] Factor XII is activated at first by negatively charged surfaces. Activated FXII subsequently activates prekallikrein to kallikrein (prekallikrein may also be activated by enzyme prolylcarboxypeptidase). Kallikrein is capable of directly converting plasminogen to plasmin and also with the help of urokinase type plasminogen activator. Plasmin and kallikrein in turn augment Factor XIIa generation thereby creating an auto-activation loop. Kallikrein generates bradykinin, a nonapeptide, from kininogen (high molecular weight form (HMWK)).[@bib6] Kallidin, a decapeptide with an additional lysine residue at the amino-terminal end of bradykinin, is generated preferentially from low molecular weight kininogen (LMWK).[@bib7] Bradykinin can also be generated from kallidin by the action of aminopeptidases. Kininase I generates active metabolites from kallidin and bradykinin, whereas, angiotensin-converting enzyme, ACE (also known as Kininase II), and aminopeptidases both inactivate bradykinin and kallidin ([Fig. 1](#fig1){ref-type="fig"}).[@bib8]Figure 1A simplified summary of the kinin metabolism and the mutual interactions between the kinin, complement, hemostatic and fibrinolytic pathways. (The blue arrows represent the augmentation of the enzymatic reactions shown in brown arrows). The sites of action of C1 esterase inhibitor (C1-INH) are represented in green chevron shapes). Abbreviations: FXII -- Factor XII, a as a suffix indicates the active form; pK -- prekallikrien; K (in bold) -- kallikrien; HMWK -- high molecular weight kininogen; LMWK -- low molecular weight kininogen; BK -- bradykinin; KD -- kallidin (lysine-bradykinin: K-BK), BK~2-9~ -- bradykinin with its first amino acid cleaved off; BK~1-7~ -- bradykinin with its last two amino acids cleaved off; Des-R BK -- bradykinin with its ninth arginine residue cleaved off; meaning of subscripts in case of kallidin (K-BK) is the same as that for bradykinin derivatives; ACE (also called kininase II) -- angiotensinogen converting enzyme, AP -- aminopeptidase, K I -- kininase I.Figure 1

Most cases of hereditary angioedema result from mutations in the gene encoding for C1 esterase inhibitor (C1-INH) protein. C1-INH belongs to *[ser]{.ul}*ine *[p]{.ul}*rotease *[in]{.ul}*hibitor (serpin) protein superfamily. This superfamily also includes other proteins such as α~1~-antitrypsin, antithrombin III, α~1~-antichymotrypsin, protein C inhibitor and heparin cofactor II. Genetic defects in these proteins have also been referred to as serpinopathies. As defects in these genes lead to conformational change in protein, its dimerization and loss of function, hence these defects may also be labeled as conformational disorders.[@bib9], [@bib10] Mutation in *SERPING1* gene leads to either decreased levels or functionally abnormal C1-INH protein. This results in loss of regulation of factor XIIa and kallikrein enzymes thereby leading to excess production of bradykinin. Bradykinin is the key molecule that mediates all clinical manifestations of HAE by acting on BR2 receptors leading to increased vascular permeability and edema.[@bib11] Other than C1-INH, defects in many other molecules involved in this pathway may lead to excess production of bradykinin and similar clinical manifestations.

Genetics of HAE {#sec3}
===============

Mutations in the *SERPING1* gene are responsible for majority of cases of hereditary angioedema. In addition, various genetic defects have also been found to result in HAE phenotype ([Fig. 2](#fig2){ref-type="fig"}).Figure 2Summary of the genetic defects leading to the phenotype of hereditary angioedema. HAE-1 (Type 1) is due to mutations leading to a quantitative defect of C1 esterase, whereas HAE-2 (Type 2) represents qualitative defects of C1-INH function. HAE-FXII and HAE-PLG pertains to defects in factor XII and plasminogen respectively. HAE-ANGPT1 corresponds to the recently described defects in the angiopoietin-1 gene leading to a hereditary angioedema like phenotype, whereas HAE-UI represents still unidentified mutations.Figure 2

*SERPING1* gene mutations (that lead to type 1 and type 2 HAE), constitute more than 95% of all cases of HAE. Clinical manifestations of CI-INH deficiency HAE are highly variable and depends upon the location of mutation in *SERPING1* gene. This gene is characterized by a remarkable allelic heterogeneity and approximately 450 different mutations have been reported as per the Human Gene Mutation Database (HGMD)[@bib12] and a similar database specifically dedicated for HAE (HAEdb, hae.enzim.hu).[@bib13] Mutations in *SERPING1* gene may be classified as shown in [Fig. 3](#fig3){ref-type="fig"}. This gene is located on chromosome 11 band position 11q12-q13.1 and has an unusual promoter devoid of TATA box. It rather contains TdT-like initiator and poly purine pyrimindine tract.[@bib14] *SERPING1* gene consists of 8 exons and 7 introns. Various exonic mutations and mutations at intron/exon junctions have been identified in this gene and these mutations are transmitted with an autosomal dominant mode of inheritance. However, approximately a quarter of all C1-INH deficiency HAE patients are sporadic in nature (i.e. they are caused by de-novo mutations in *SERPING1* gene).[@bib15] Since the availability of various mutations reported in *SERPING1* gene, it has become easier to predict the structural and functional attributes of this gene thereby explaining the phenomena of allelic heterogeneity.[@bib16], [@bib17] *SERPING1* gene is an example of mutagenic liability and various theories have been postulated for the same: 1) *SERPING1* gene is located near centromeric region; 2) Presence of 17 Alu repeats on intron 7 of the gene makes it a hotspot for non-homologous recombination and causes partial deletions or duplication in the gene,[@bib18] characterized by absence of protein product accounting for approximately 15--20% of all cases of CI-INH deficiency HAE; 3) Presence of CpG sites in the coding part of the gene predisposes it for mutations due to spontaneous deamination. The 466th residue of gene encodes for the arginine amino acid (CGC) that forms the reactive center of CI-INH and CpG is a natural target for recurrent amino acid substitution.[@bib19]Figure 3Various mutations reported in *SERPING1* gene.Figure 3

Missense mutations constitute approximately 30--40% of all mutations in *SERPING1* gene.[@bib20], [@bib21] Various nonsense and indel mutations lead to addition of premature stop codon and frame-shift mutations that eliminate protein synthesis via nonsense mediated mRNA decay.[@bib22]

Single Nucleotide Polymorphisms (SNPs) in *SERPING1* gene have also been found to be associated with some non-HAE disease conditions; e.g. rs4926 \[c.1438G\>A, p.V480M\] polymorphism is a missense variant in the coding region and has been found to be associated with staphylococcal carriage of the anterior nares.[@bib23] In Caucasian populations, presence of intron 6 SNP (rs2511989) in *SERPING1* gene has been found to be associated with age related macular degeneration.[@bib24]

Factor XII gene {#sec4}
===============

In the year 2000, Bork et al described another type of HAE with a quantitatively and qualitatively normal C1-INH (labeled as nlC1-INH-HAE). In this rare type of HAE, clinical manifestations were found to be similar to classical type 1 and 2 HAE but no mutation was detected in the *SERPING1* gene. The genetic defect for this type of HAE was discovered in the year 2006 when two missense mutations (p.Thr309Lys and p.Thr309Arg) in *F12* gene were detected for the first time in a German family ([Table 1](#tbl1){ref-type="table"}).[@bib25], [@bib26]Table 1Summary of the mutations described in *F12*, plasminogen (*PLG*) and angiopoietin (*ANGPT1*) genes resulting in HAE.Table 1S noGene nameVariant observed in HAE1.*F12*Exon 9 missense variants (p.Thr328Lys) and (p.Thr328Arg)\
Exon 9/intron 9 boundary large deletion of 72 bp (c.971_1018 + 24del72) duplication of 18 bp (c.892_909dup)2.Plasminogen (*PLG*)Exon 9 missense variant (c.988 A\>G), (p.Lys330Glu)3.Angiopoietin (*ANGPT1*)Missense mutation c.807G\>T, p.Ala119Ser

Over the next few years after discovery of mutations in *F12* gene, researchers found out that these mutations lead to increased production of activated Factor XII (Factor XIIa) via plasmin.[@bib27], [@bib28] This also provides an insight into the effect of anti-fibrinolytic medications in this type of HAE. Around 300 patients with *F12* gene mutations have been reported till date (OMIM\#610619). *F12* gene has a size of 12 kb and comprises of 14 exons.[@bib29] The promoter of the *F12* gene is similar but not identical to the promoter of the estrogen responsive elements (EREs) gene. Because of this similarity, estrogen also enhances the concentration of FXII in the plasma and may produce manifestations similar to this type of HAE.[@bib30] *F12* gene mutation associated with HAE is a gain of function mutation and is transmitted in an autosomal dominant mode of inheritance.[@bib31] Four most common pathogenic mutations in this gene have been identified so far. These include 2 missense variants in exon 9 (p.Thr328Lys and p.Thr328Arg); 72 bp deletion (c.971_1018 + 24del72) in two unrelated families from Turkey; mutation at the exon 9/intron 9 junction[@bib22], [@bib32] and 18 bp duplication (c.892_909dup) in a Hungarian family causing repetition of 6 amino acids (p.298--303) at the same locus.[@bib33] The clinical phenotype of HAE caused by mutations in *F12* gene is similar to C1INH deficiency HAE except that there is higher female predominance, more aggravation during pregnancy and more estrogen dependency.[@bib34] Complement C4 and C1-INH activity is often normal except occasionally during the attack. Assessment of activity of coagulation factor XII is not reliable for diagnosis.

Plasminogen gene {#sec5}
================

Plasminogen is inactive precursor protein of the enzyme plasmin. Plasmin plays its role in bradykinin production via activation of factor XII. A newly identified missense mutation in exon 9 of plasminogen (*PLG*) gene, c.988A\>G (or named as c.1100A\>G depending upon the assembly used), describes glutamic acid replacing lysine at position 330 (p.Lys330Glu) (or named as p.Lys311Glu depending on the numbering scheme used).[@bib35], [@bib36] Interestingly, the same mutation has been described by various groups in about 25 families from different countries with affected individuals numbering more than 100 ([Table 1](#tbl1){ref-type="table"}).[@bib37] The mutation leads to change in the kringle 3 domain which alters the structure of the wild-type protein. The mutant protein leads to the increased production of the bradykinin thereby resulting in HAE. Clinical profile of patients with plasminogen mutation is different from C1INH deficiency HAE. Patients with plasminogen gene mutation present usually in adulthood as compared to pediatric onset in majority of patients with C1-INH deficiency HAE. In addition, these patients tend to have higher chances of head and neck swellings (tongue, face, laryngeal edema) and relatively less chances of extremity edema or swelling of the genitals. ACE inhibitors and Angiotensin 1 receptor blockers tend to precipitate the attacks. Icatibant, tranexamic acid seem to be the most effective drugs.[@bib35], [@bib38], [@bib39], [@bib40]

Angiopoietin 1 gene {#sec6}
===================

A novel mutation was identified in angiopoietin 1 (*ANGPT1*) gene using whole exome sequencing (WES) in patients with normal C1-INH HAE ([Table 1](#tbl1){ref-type="table"}).[@bib41] This was an unusual mutation as this gene has not been shown to be associated with hemostatic system or kinin pathway. It has also been shown that p.Ala119Ser mutation reduces the plasma levels of ANGPT1 protein and further hampers its ability to form multimers. Deficiency of ANGPT1 protein leads to reduced ability of mutant protein to bind to its cognate receptor tunica interna endothelial cell kinase 2 (TIE2). This signaling cascade is involved instabilizing vasculature and diminishing vascular permeability. ANGPT2 protein, on the other hand, antagonizes ANGPT1 protein leading to enhanced vascular permeability. The ratio of ANGPT1/ANGPT2 was found to be decreased in patients with p.Ala119Ser mutation.[@bib42] A simplified summary of the pathogenic mechanism involved in HAE caused by *ANGPT1* gene mutation is shown in [Fig. 4](#fig4){ref-type="fig"}.[@bib43] Discovery of novel pathways in the pathogenesis of HAE have remarkably opened new frontiers in understanding and managing this disease.Figure 4Counteracting influences of angiopoietin 1 and bradykinin on vascular endothelial cells. Angiopoietin 1 acting via TIE 2 receptor reinforces the cell cytoskeletal arrangements and decreases the vascular permeability. While, bradykinin disrupts this orderly arrangement leading to increased vascular permeability.Figure 4

Laboratory evaluation of patients with a clinical suspicion of HAE {#sec7}
==================================================================

The initial laboratory workup for hereditary angioedema is shown in [Fig. 5](#fig5){ref-type="fig"}. For genetic testing of HAE, molecular analysis is to be carried out for the genes associated with HAE. In the classical form of type 1 and type II HAE *SERPING1* gene is the prominent target. Initially all the eight exons of *SERPING1* gene with intronic/exonic junctions are amplified using oligonucleotides. Using MLPA kit, probe amplification depending on Multiplex Ligation can be done[@bib44], [@bib45] when all the eight exons data of *SERPING1* gene is clear than one might expect some large gene rearrangements like insertion/deletions. For other genes like *F12*, plasminogen and angiopoietin diseases associated exons are amplified with oligonucleotides and checked for the variants using Sanger sequencing. In addition, next generation sequencing (NGS) panel including all genes known to cause HAE and several other genes that may potentially lead to HAE may be utilized for diagnosis with an additional advantage of identifying newer genetic defects.Figure 5Proposed diagnostic algorithm for evaluation of a suspected case of hereditary angioedema (HAE with normal C1 inhibitor function requires genetic analysis for diagnosis).Figure 5

Treatment {#sec8}
=========

Treatment of HAE has evolved with advancement in understanding the pathogenesis of this disease and is either directed towards replacing the defective protein or blocking various molecules involved in the production of bradykinin or the bradykinin receptor ([Fig. 6](#fig6){ref-type="fig"}). In addition to various preparations of C1-INH analogues, other therapeutic options available include icatibant, a parenterally administered bradykinin receptor type 2 antagonist; ecallantide, a parenterally administered kallikrein inhibitor[@bib46], [@bib47]; Landelumab, a monoclonal antibody targeting kallikrein[@bib48] and a novel molecule BCX7353, an oral kallikrein inhibitor.[@bib49] Other management options include fresh frozen plasma (FFP)/single donor plasma (SDP) \[aimed at replacing the defective or insufficient C1-INH\]; attenuated androgens and tranexamic acid. Androgens act by augmenting bradykinin inactivation via aminopeptidase enzyme and by increasing the production of C1-INH.[@bib50], [@bib51] Tranexamic acid limits the production of plasmin by blocking the cleavage of its proenzyme plasminogen ([Table 2](#tbl2){ref-type="table"}).[@bib52], [@bib53]Figure 6Therapeutic modalities employed in the management of hereditary angioedema. (The blue arrows represent the augmentation of the enzymatic reactions shown in brown arrows; the green arrows with a plus sign indicate therapies for replacement or augmentation of the target product, while the red arrows with a minus sign indicate inhibitions. The sites of action of C1 esterase inhibitor (C1-INH) are represented in green chevron shapes). Abbreviations: FXII -- Factor XII, a as a suffix indicates the active form; pK -- prekallikrien; K (in bold) -- kallikrien; HMWK -- high molecular weight kininogen; LMWK -- low molecular weight kininogen; BK -- bradykinin; KD -- kallidin (lysine-bradykinin: K-BK), BK~2-9~ -- bradykinin with its first amino acid cleaved off; BK~1-7~ -- bradykinin with its last two amino acids cleaved off; ACE (also called kininase II) -- angiotensinogen converting enzyme, AP -- aminopeptidase, K I -- kininase I, TA -- tranexamic acid, EACA -- epsilon amino caproic acid.Figure 6Table 2Summary of effective treatment options for hereditary angioedema.Table 2Therapeutic optionsUsesSuggested dosesRemarksDanazol\
Stanozolol\
Oxandrolone\
(Weak androgens)Short term &\
Long term prophylaxisDanazol - STP: 2.5--10 mg/kg/day (maximum 600 mg/day). LTP: 2.5--5 mg/kg/day (maximum 200 mg/day).Easily available. Undesirable virilising effect, weight gain, acne, headaches, menstrual irregularities, depression.Tranexamic acid Epsilon aminocaproic acidShort term &\
Long term prophylaxisTranexamic acid: 20--50 mg/kg/day in 2 or 3 divided doses (maximum 3--6 g/day).Can be used in pregnancy if benefits outweigh risk (category B)FFP (fresh frozen plasma)/\
SDP (solvent detergent plasma)Short term prophylaxis\
Acute treatment10 ml/kg/doseEasily available, inexpensive. Concern of infections with regular use.C1 esterase inhibitorspdC1-INH~Be~ for short term prophylaxis, acute treatmentpdC1-INH~Be~ 15--30 units/kg/dose IV.Expensive, currently unavailable in many Asian countries. One unit parallels the amount of C1INH in 1 ml of plasma of a normal individual.pdC1-INH~Ci~ for long term prophylaxis, acute treatmentpdC1-INH~Ci~ 10--20 units/kg/dose once or twice weekly (initial maximum dose 1000 units).rhC1-INH for acute treatment, long term prophylaxisrhC1-INH 50 units/kg/dose and is given by intravenous injection.Subcutaneous preparations are also available.EcallantideAcute treatment30 mg/dose subcutaneous injectionExpensive, risk of anaphylaxis. Not available in many Asian countries.IcatibantAcute treatment30 mg/dose subcutaneous injection (maximum three doses/day)Expensive. Not available in many Asian countries. Local reactions.LanadelumabLong term prophylaxisDose range 150--300 mg every 2--4 weeks.Pediatric dosing yet to be established.BCX7353Long term prophylaxisMinimum effective dose used: 125 mg/day

Future perspectives {#sec9}
===================

HAE is a heterogeneous disease with complex pathophysiology that has been studied extensively. Despite detailed research and identification of novel defects, a proportion of patients with HAE are still labeled as HAE-Unidentified (HAE-UI) wherein the genetic defect has not yet been identified. There are several molecules involved in the pathway for production of bradykinin and mutations in genes encoding these molecules may be potential genetic etiology for HAE-UI. These could include activating mutations in Kallikrein gene; activating mutations in Bradykinin gene or its receptor; activation mutations in Kininase 1 gene and loss of function mutations in gene encoding aminopeptidase and ACE enzymes. There is a possibility that mutations in these and other related genes could be potential modifiers in the clinical phenotype of patients with known genetic causes of HAE. A recent study analyzed polymorphisms in 15 such genes and their effect on the clinical phenotype of patients with C1-INH HAE/FXII-HAE. Amongst several variants that were identified in this study, 5 were classified as probably pathogenic. These included p.Y244C, p.G354R, p.T916M in the ACE gene; p.C548Y in KLKB1 (kallikrein) gene and p.D287N in NOS3 (nitric oxide synthase) gene. However, the effect of these mutations on the final clinical phenotype was found to be rather complex. In patients with c.-22-2A\>G mutations in C1-INH gene, p.Y244C resulted in infrequent attacks as compared to p.T916M. However, in patients with c.889G\>A mutation in C1-INH gene, the clinical phenotype was very different even with the same variant p.G354R in the ACE gene.[@bib54] Identification of these novel polymorphisms in several genes leading to modification in the clinical phenotype of HAE is a relatively recent phenomenon. This needs more research work and needs to be studied in several other populations.

In addition, the recent discovery of *ANGPT1* gene mutation in an Italian family with HAE-UI phenotype has expanded our understanding about this disease beyond the complement, kinin cascade. This discovery has also raised several questions for researchers that in the process of finding out novel genes for HAE, they not only need to work on above mentioned potential genes involved in pathway of bradykinin synthesis but several other pathways as well. Increasing number of novel mutations in the *ANGPT1* gene are now being reported to be associated with the HAE phenotype \[c.23C\>T (p.A8V) and c.1110G\>C (p.Q370H)\].[@bib55]

Apart from this, several novel mutations are likely to be discovered in populations wherein the genetic etiology of HAE has not been evaluated till date. In our experience, we analyzed our cohort of pediatric HAE patients and found novel mutations in *SERPING1* gene from 3 families (unreported data). Discovery of new genetic etiologies is likely to bring new therapeutic options in the management of patients with HAE.
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